Drugs in the Pipeline for HBV.

Chronic hepatitis B remains a significant cause of morbidity and mortality worldwide. Most hepatitis B virus (HBV)-infected individuals are neither diagnosed nor treated. In those treated, nucleos(t)ide polymerase inhibitors persistently suppress viremia to the limits of quantitation; however, few achieve a "functional cure," defined as sustained off-treatment loss of detectable serum HBV DNA with or without loss of hepatitis B surface antigen. The low cure rate has been attributed to an inability to eliminate the viral reservoir of covalently closed circular DNA from hepatocytes. This review focuses on the diverse therapeutic approaches currently under development that may contribute to the goal of HBV cure.

• Publication year

  2019

• Venue

  Clinical Liver Disease

• Publication date

  2019-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CLD.2019.04.006PMID 31266626
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers

  2021cited by this paper
• Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus infected hepatocytes.

  2019cited by this paper
• Sustained off‐treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced HBeAg seroconversion

  2019cited by this paper
• Inhibition of HBV replication by N‐hydroxyisoquinolinedione and N‐hydroxypyridinedione ribonuclease H inhibitors

  2019cited by this paper
• Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.

  2019cited by this paper
• PS-150-Evidence for the presence of infectious virus in the serum from chronic hepatitis B patients suppressed on nucleos (t)ide therapy with detectable but not quantifiable HBV DNA

  2019cited by this paper
• Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.

  2019cited by this paper
• PAPD5/7 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization

  2019cited by this paper
• Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection.

  2019cited by this paper
• Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

  2019cited by this paper
• Therapeutic vaccination for chronic hepatitis B: A systematic review and meta‐analysis

  2019cited by this paper
• Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives.

  2019cited by this paper
• RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV

  2018cited by this paper
• In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule capsid assembly modulator for the treatment of chronic hepatitis B

  2018cited by this paper
• Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizer

  2018cited by this paper
• Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial

  2018cited by this paper
• Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B

  2018cited by this paper
• TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

  2018cited by this paper
• Novel and potent HBV capsid modulator reduces HBeAg and cccDNA in core site directed T109I mutant in HepNTCP cells

  2018cited by this paper
• RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated

  2018cited by this paper
• Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study

  2018cited by this paper
• Hepatitis B virus core protein allosteric modulators can distort and disrupt intact capsids

  2018cited by this paper
• siRNA drug development against hepatitis B virus infection

  2018cited by this paper
• Discovery of Novel Hepatitis B Virus Nucleocapsid Assembly Inhibitors.

  2018cited by this paper
• Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination.

  2018cited by this paper
• AGK2, A SIRT2 Inhibitor, Inhibits Hepatitis B Virus Replication In Vitro And In Vivo

  2018cited by this paper
• Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.

  2018cited by this paper
• Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

  2018cited by this paper
• PD-1 blockade partially recovers dysfunctional virus–specific B cells in chronic hepatitis B infection

  2018cited by this paper
• Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice

  2018cited by this paper
• Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)

  2018cited by this paper
• The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals.

  2018cited by this paper
• Safety and efficacy of vesatolimod (GS‐9620) in patients with chronic hepatitis B who are not currently on antiviral treatment

  2018cited by this paper
• Immunotherapy for Chronic Hepatitis B Virus Infection

  2018cited by this paper
• Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues

  2018cited by this paper
• Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.

  2018cited by this paper
• Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B

  2018cited by this paper
• Preclinical study of a combinatorial RNAi/vaccination therapy as a potential cure for chronic hepatitis B

  2017cited by this paper
• No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment

  2017cited by this paper
• Novel viral and host targets to cure hepatitis B.

  2017cited by this paper
• Therapeutic vaccination for chronic hepatitis B.

  2017influential reference
• RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg

  2017cited by this paper
• HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways

  2017cited by this paper
• Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives

  2017cited by this paper
• New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review

  2017cited by this paper
• Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation

  2017cited by this paper
• Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.

  2017cited by this paper
• Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.

  2017cited by this paper
• The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells

  2017cited by this paper
• Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model

  2017cited by this paper
• Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON)

  2017cited by this paper
• Hepatitis B core protein as a therapeutic target

  2017cited by this paper
• Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B

  2017cited by this paper
• Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

  2017cited by this paper
• Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

  2016cited by this paper
• Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520

  2016influential reference
• Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.

  2016cited by this paper
• Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

  2016cited by this paper
• The role of innate immunity in the immunopathology and treatment of HBV infection.

  2016cited by this paper
• Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection

  2016cited by this paper
• Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B

  2016cited by this paper
• Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

  2016cited by this paper
• Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

  2016cited by this paper
• Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection.

  2016cited by this paper
• Reciprocal regulation of farnesoid X receptor α activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes

  2016cited by this paper
• Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers

  2016cited by this paper
• DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus

  2016cited by this paper
• Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.

  2016cited by this paper
• The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.

  2016cited by this paper
• Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)

  2015cited by this paper
• Molecular biology of hepatitis B virus infection.

  2015cited by this paper
• The hepatitis B virus ribonuclease H as a drug target.

  2015cited by this paper
• Core protein: A pleiotropic keystone in the HBV lifecycle.

  2015cited by this paper
• The Interface between Hepatitis B Virus Capsid Proteins Affects Self-Assembly, Pregenomic RNA Packaging, and Reverse Transcription

  2015cited by this paper
• The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus.

  2015cited by this paper
• Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.

  2015cited by this paper
• Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.

  2015cited by this paper
• Targeting hepatitis B virus cccDNA using CRISPR/Cas9.

  2015cited by this paper
• Assembly and Release of Hepatitis B Virus.

  2015cited by this paper
• A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.

  2014cited by this paper
• Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity.

  2014cited by this paper
• Strategies to inhibit entry of HBV and HDV into hepatocytes.

  2014cited by this paper
• Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance

  2014cited by this paper
• The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo

  2014cited by this paper
• AAV-Mediated Delivery of Zinc Finger Nucleases Targeting Hepatitis B Virus Inhibits Active Replication

  2014cited by this paper
• Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.

  2014cited by this paper
• Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection

  2014cited by this paper
• Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline

  2014cited by this paper
• Sodium-dependent taurocholic cotransporting polypeptide: a candidate receptor for human hepatitis B virus

  2013cited by this paper
• Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes

  2013cited by this paper
• GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.

  2013cited by this paper
• Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection

  2013cited by this paper
• Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

  2012cited by this paper
• Clinical Implications of HBsAg Quantification in Patients with Chronic Hepatitis B

  2012influential reference
• IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.

  2012cited by this paper
• Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-α-2A Therapy

  2011cited by this paper
• Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline

  2010cited by this paper
• The Host–pathogen Interaction during HBV Infection: Immunological Controversies

  2010cited by this paper
• Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

  2010cited by this paper
• RNAi for Treating Hepatitis B Viral Infection

  2007cited by this paper

• Panduratin A from Boesenbergia rotunda suppresses hepatitis B virus by targeting HNF1α and synergizing with antiviral agents

  2026cites this paper
• Cytokine and chemokine profiling in chronic hepatitis C and B virus infections with high viral load.

  2024cites this paper
• Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations

  2024cites this paper
• Structure-based Design of Novel Hepatitis B Virus Capsid Assembly Modulators.

  2023cites this paper
• A Historical Overview on the Role of Hepatitis B and C Viruses as Aetiological Factors for Hepatocellular Carcinoma

  2023cites this paper
• Avenanthramides, Distinctive Hydroxycinnamoyl Conjugates of Oat, Avena sativa L.: An Update on the Biosynthesis, Chemistry, and Bioactivities

  2023cites this paper
• A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B.

  2023cites this paper
• Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure

  2023influential citation
• Vaccination Campaign against Hepatitis B Virus in Italy: A History of Successful Achievements

  2023cites this paper
• Five Decades of HBV Infection in Italy: A Continuous Challenge

  2023cites this paper
• Therapeutic Advances in Viral Hepatitis A–E

  2022cites this paper
• Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens

  2022cites this paper
• Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy

  2022cites this paper
• Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir

  2022cites this paper
• A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection

  2022cites this paper
• Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment

  2022cites this paper
• A Polysaccharide From Eupolyphaga sinensis Walker With Anti-HBV Activities In Vitro and In Vivo

  2022cites this paper
• Identification of domestic cat hepadnavirus from a cat blood sample in Japan

  2022cites this paper
• Critical Updates on Chronic Hepatitis B Virus Infection in 2021

  2021cites this paper
• Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication.

  2021cites this paper
• Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays.

  2021cites this paper
• Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B

  2021cites this paper
• Achieving a Cure: The Next Frontier in Hepatitis B Treatment

  2021cites this paper
• Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection

  2021influential citation
• Recent Advances in Hepatitis B Treatment

  2021influential citation
• Hepatitis B virus–host interactions and novel targets for viral cure

  2021cites this paper
• Humanized virus-suppressing factor inhibits hepatitis B virus infection by targeting viral cell entry

  2021cites this paper
• Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

  2021cites this paper
• Treatments for HBV: A Glimpse into the Future

  2021cites this paper
• Emerging Biomarkers for HBV Cure: HBsAg and Beyond

  2021cites this paper
• Management of Patients With Chronic Hepatitis B (Hepadnaviridae) and Chronic Hepatitis D Infection (Deltavirus)

  2021cites this paper
• Direct‐Acting Antivirals for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

  2021cites this paper
• Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi

  2020cites this paper
• Targeting Viral cccDNA for Cure of Chronic Hepatitis B

  2020cites this paper
• Novel biomarkers for the management of chronic hepatitis B

  2020cites this paper
• Will we need novel combinations to cure HBV infection?

  2020cites this paper
• Can we cure hepatitis B virus with novel direct‐acting antivirals?

  2020cites this paper
• Editorial: HBV—the promise of a new era in therapeutics

  2020cites this paper
• De nouvelles cibles thérapeutiques pour la guérison de l’hépatite chronique B

  2020cites this paper
• Advances in hepatitis B therapeutics

  2020cites this paper
• Bifunctional macromolecule activating both OX40 and interferon-α signaling displays potent therapeutic effects in mouse HBV and tumor models.

  2020cites this paper
• Newer drugs for the treatment of hepatitis B viral infection

  2020cites this paper
• Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019

  2020cites this paper
• Repurposing Nucleoside Analogs for Human Coronaviruses

  2020cites this paper
• Overview of anti-Hepatitis B virus agents

  2020cites this paper
• Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss

  2020cites this paper
• CASTELO: clustered atom subtypes aided lead optimization—a combined machine learning and molecular modeling method

  2020cites this paper
• Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.

  2020cites this paper
• Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection

  2020cites this paper
• Aerobic glycolysis supports hepatitis B virus protein synthesis through interaction between viral surface antigen and pyruvate kinase isoform M2

  2020cites this paper
• Prevention and Management of HBV in Organ Transplantation

  2020cites this paper
• Core inhibitor therapy for chronic hepatitis B.

  2019cites this paper
• Chaperone-Mediated Autophagy in the Liver: Good or Bad?

  2019cites this paper
• A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System

  2019cites this paper
• Antiviral effects of a niobium‐substituted heteropolytungstate on hepatitis B virus‐transgenic mice

  2019cites this paper
• Synthetic therapeutics for the treatment of hepatitis B during pregnancy

  2018cites this paper